LB Pharmaceuticals Inc
LBRX23.820USD
-0.040-0.17%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
602.62MMarket Cap
LossP/E TTM
More Details of LB Pharmaceuticals Inc Company
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
LB Pharmaceuticals Inc Info
Ticker SymbolLBRX
Company nameLB Pharmaceuticals Inc
IPO dateSep 11, 2025
CEOTurner (Heather D)
Number of employees16
Security typeOrdinary Share
Fiscal year-endSep 11
AddressOne Pennsylvania Plaza, Suite 1025
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10119
Phone19174506581
Websitehttps://lbpharma.us/
Ticker SymbolLBRX
IPO dateSep 11, 2025
CEOTurner (Heather D)
Company Executives of LB Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Zachary Prensky
Mr. Zachary Prensky
Co-Founder, Director
Co-Founder, Director
61.27K
+61274.00%
Mr. Marc L. Panoff, CPA
Mr. Marc L. Panoff, CPA
Senior Vice President - Finance
Senior Vice President - Finance
10.24K
+10242.00%
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Chief Executive Officer, Member of our Board of Director
Chief Executive Officer, Member of our Board of Director
--
--
Mr. Gad Soffer
Mr. Gad Soffer
Chief Business Officer
Chief Business Officer
--
--
Dr. Anna Eramo, M.D.
Dr. Anna Eramo, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Silva, Ph.D.
Mr. Richard Silva, Ph.D.
Senior Vice President of Technical Operations
Senior Vice President of Technical Operations
--
--
Mr. Scott Garland
Mr. Scott Garland
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Rajul Jain, M.D.
Dr. Rajul Jain, M.D.
Independent Director
Independent Director
--
--
Ms. Rebecca Luse
Ms. Rebecca Luse
Independent Director
Independent Director
--
--
Mr. Ran Nussbaum
Mr. Ran Nussbaum
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Zachary Prensky
Mr. Zachary Prensky
Co-Founder, Director
Co-Founder, Director
61.27K
+61274.00%
Mr. Marc L. Panoff, CPA
Mr. Marc L. Panoff, CPA
Senior Vice President - Finance
Senior Vice President - Finance
10.24K
+10242.00%
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Chief Executive Officer, Member of our Board of Director
Chief Executive Officer, Member of our Board of Director
--
--
Mr. Gad Soffer
Mr. Gad Soffer
Chief Business Officer
Chief Business Officer
--
--
Dr. Anna Eramo, M.D.
Dr. Anna Eramo, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Silva, Ph.D.
Mr. Richard Silva, Ph.D.
Senior Vice President of Technical Operations
Senior Vice President of Technical Operations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 17 hours ago
Updated: 17 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deep Track Capital LP
13.25%
RA Capital Management, LP
7.02%
TCG Crossover Management, LLC
6.90%
Commodore Capital LP
5.93%
Pontifax Venture Capital
5.58%
Other
61.32%
Shareholders
Shareholders
Proportion
Deep Track Capital LP
13.25%
RA Capital Management, LP
7.02%
TCG Crossover Management, LLC
6.90%
Commodore Capital LP
5.93%
Pontifax Venture Capital
5.58%
Other
61.32%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.38%
Venture Capital
24.96%
Investment Advisor
24.11%
Investment Advisor/Hedge Fund
10.64%
Institution
2.64%
Research Firm
1.70%
Sovereign Wealth Fund
0.72%
Individual Investor
0.31%
Bank and Trust
0.10%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
62
22.24M
0.00%
--
2025Q4
77
25.00M
98.80%
+24.26M
2025Q3
10
12.02M
47.50%
+12.02M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deep Track Capital LP
3.35M
13.25%
+3.35M
--
Sep 30, 2025
RA Capital Management, LP
1.78M
7.02%
+1.78M
--
Sep 30, 2025
TCG Crossover Management, LLC
1.75M
6.9%
+1.75M
--
Sep 30, 2025
Commodore Capital LP
1.50M
5.93%
+1.50M
--
Sep 30, 2025
Pontifax Venture Capital
1.41M
5.58%
+1.41M
--
Sep 12, 2025
Logos Global Management LP
1.13M
4.47%
+1.13M
--
Sep 30, 2025
Balyasny Asset Management LP
968.27K
3.83%
+968.27K
--
Sep 30, 2025
VV Manager LLC
883.68K
3.49%
+883.68K
--
Sep 12, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
